Risk of MS relapse after yellow fever vaccination
A self-controlled case series
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 22, 2019
- Accepted in final form March 20, 2020
- First Published May 1, 2020.
Author Disclosures
- Angela Huttner, MD,
- Gilles Eperon, MD,
- Agustina M. Lascano, MD, PhD,
- Serge Roth, MD,
- Jean-Marc Schwob, MD,
- Claire-Anne Siegrist, MD and
- Patrice H. Lalive, MD
- Angela Huttner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Swiss National Science Foundation, 74th National Research Program ÂSmarter Health Care (no. 407440_167359), PI (unrelated trial on antibiotic duration in gram-negative bacteremia), 2017-2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gilles Eperon, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Academic fund (Hopitaux Universitaires de Genève et Université de Genève, Fonds MIMOSA) for another study (on-going) on vaccinal immunogenicity for MS patients with NSB/FGD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Agustina M. Lascano, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Serge Roth, MD,
Fees for Advisory Boards from Novartis, Biogen, Merk,Teva, Sanofi-Genzyme, Roche
NONE
Travel grants from Novartis, Biogen, Merk, Teva, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Marc Schwob, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claire-Anne Siegrist, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrice H. Lalive, MD
(1) Biogen-Idec (2) Novartis (3) Merck (4) Roche
NONE
(1) Biogen-Idec (2)Teva (3) Merck (4) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Center for Vaccinology (A.H., C.-A.S.), University of Geneva; Division of Infectious Diseases (A.H.), Geneva University Hospitals; Division of Tropical and Humanitarian Medicine (G.E., J.-M.S.), Geneva University Hospitals; Department of Neurosciences (A.M.L., S.R., P.H.L.), Division of Neurology, Unit of Neuroimmunology and Neuromuscular Diseases, Geneva University Hospitals; Department of Pathology and Immunology (C.-A.S., P.H.L.), Faculty of Medicine, University of Geneva; and Division of Laboratory Medicine (P.H.L.), Department of Diagnostic, Geneva University Hospitals, Switzerland.
- Correspondence
Dr. Lalive patrice.lalive{at}hcuge.ch
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.